Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas C Throckmorton

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Journal of Electrocardiology|November 10, 2004
Regulatory advice on evaluation of the proarrhythmic potential of drugsNorman Stockbridge, Douglas C Throckmorton
Clinical Journal of the American Society of Nephrology : CJASN|April 22, 2015
Shortage of Peritoneal Dialysis Solution and the Food and Drug Administration's ResponseValerie Jensen, Douglas C Throckmorton
Clinical Pharmacology and Therapeutics|March 24, 2018
The FDA's Approach to the Prescription Opioid ProblemJanet Woodcock, Douglas C Throckmorton
Annals of Internal Medicine|August 25, 2018
Combined Gabapentinoid and Opioid Use: The Consequences of Shifting Prescribing TrendsDouglas C Throckmorton, Janet Woodcock
Journal of Oncology Practice|April 24, 2019
US Food and Drug Administration Efforts to Support Pain Management and Opioid Access to Patients With CancerSharon H Hertz, Douglas C Throckmorton
The New England Journal of Medicine|May 31, 2018
The FDA and the Next Wave of Drug Abuse - Proactive PharmacovigilanceDouglas C Throckmorton, Scott Gottlieb, Janet Woodcock
The New England Journal of Medicine|October 5, 2012
Management of opioid analgesic overdoseDouglas C Throckmorton, Wilson M Compton, Peter Lurie
Annals of Internal Medicine|March 19, 2019
Storage and Disposal of Opioid AnalgesicsMark A Liberatore, Judith A Racoosin, Douglas C Throckmorton
JAMA Internal Medicine|January 27, 2016
Effect of US Drug Enforcement Administration's Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic PrescribingChristopher M Jones, Peter G Lurie, Douglas C Throckmorton
Expert Review of Clinical Pharmacology|November 26, 2011
Adverse effects in women: implications for drug development and regulatory policiesAmeeta Parekh, Emmanuel O Fadiran, Kathleen Uhl, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Journal of Electrocardiology|November 10, 2004
Regulatory advice on evaluation of the proarrhythmic potential of drugsNorman Stockbridge, Douglas C Throckmorton
Clinical Journal of the American Society of Nephrology : CJASN|April 22, 2015
Shortage of Peritoneal Dialysis Solution and the Food and Drug Administration's ResponseValerie Jensen, Douglas C Throckmorton
Clinical Pharmacology and Therapeutics|March 24, 2018
The FDA's Approach to the Prescription Opioid ProblemJanet Woodcock, Douglas C Throckmorton
Annals of Internal Medicine|August 25, 2018
Combined Gabapentinoid and Opioid Use: The Consequences of Shifting Prescribing TrendsDouglas C Throckmorton, Janet Woodcock
Journal of Oncology Practice|April 24, 2019
US Food and Drug Administration Efforts to Support Pain Management and Opioid Access to Patients With CancerSharon H Hertz, Douglas C Throckmorton
The New England Journal of Medicine|May 31, 2018
The FDA and the Next Wave of Drug Abuse - Proactive PharmacovigilanceDouglas C Throckmorton, Scott Gottlieb, Janet Woodcock
The New England Journal of Medicine|October 5, 2012
Management of opioid analgesic overdoseDouglas C Throckmorton, Wilson M Compton, Peter Lurie
Annals of Internal Medicine|March 19, 2019
Storage and Disposal of Opioid AnalgesicsMark A Liberatore, Judith A Racoosin, Douglas C Throckmorton
JAMA Internal Medicine|January 27, 2016
Effect of US Drug Enforcement Administration's Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic PrescribingChristopher M Jones, Peter G Lurie, Douglas C Throckmorton
Expert Review of Clinical Pharmacology|November 26, 2011
Adverse effects in women: implications for drug development and regulatory policiesAmeeta Parekh, Emmanuel O Fadiran, Kathleen Uhl, et al.
Pageof 2